Amylin Pharmaceuticals Announces Public Offering of Common Stock
March 30 2006 - 7:30AM
PR Newswire (US)
SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced a public
offering of 10,000,000 shares of common stock at a price of $46.50
per share, resulting in estimated net proceeds to Amylin of
approximately $441.4 million. The Company has granted to the
underwriters an option to purchase up to 1,500,000 additional
shares of common stock from the company to cover over-allotments,
if any, within 30 days from the date of the prospectus supplement.
Morgan Stanley & Co. Incorporated is acting as the sole
bookrunning and co-lead manager for the offering. Goldman, Sachs
& Co. is acting as a co-lead manager of the offering.
Co-managers for the offering are Bear, Stearns & Co. Inc. and
Lehman Brothers Inc. Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines. Copies
of the prospectus supplement may be obtained, when available, from
the Prospectus Department of Morgan Stanley & Co. Incorporated
(1585 Broadway, New York, New York 10036, phone 212-761-6775, fax
212-761-0211). DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT:
Mark G. Foletta, Senior Vice President, Finance and Chief Financial
Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024